Cell Origin Subtypes Predict Outcomes in Localized-Stage Diffuse Large B-Cell Lymphoma Treated with Curative Radiotherapy

DOI: 10.4236/jct.2013.43A058   PDF   HTML     3,189 Downloads   4,915 Views  

Abstract

Diffuse large B-cell lymphoma (DLBCL) is regarded as a heterogeneous group of lymphomas. The aims of this study were to determine the clinical significance and prognostic value of different immunophenotypic profiles in localized-stage head and neck DLBCL treated with curative radiotherapy. We included 102 localized-stage head and neck DLBCL patients in this study. We classified DLBCL patients into germinal center B-cell (GCB) and non-GCB groups by immunohistochemical analysis. Statistical analysis was used to correlate the GCB and non-GCB subgroups, CD5 and Ki67 expression, B-ALPS (a modified International Prognostic Index for early stage lymphoma), chemotherapy regimen, and sex. Multivariate analysis was performed using the Cox proportional hazard regression model to compare cause-specific survival (CSS) and relapse-free rate (RFR) distributions. The cell of origin classification (GCB or non-GCB subtypes) was an independent predictor of CSS (p = 0.040) and RFR (p = 0.023). In the non-GCB group, chemotherapy with rituximab was an independent predictor of CSS. In conclusion, this study shows that the prognosis of the non-GCB group was significantly poorer than that of the GCB group, and that rituximab improved CSS in localized-stage head and neck DLBCL, especially in the non-GCB group.

Share and Cite:

Y. Watanabe, H. Suefuji, E. Ogo, K. Sato, T. Nakashima, T. Okamura, K. Ohshima and N. Hayabuchi, "Cell Origin Subtypes Predict Outcomes in Localized-Stage Diffuse Large B-Cell Lymphoma Treated with Curative Radiotherapy," Journal of Cancer Therapy, Vol. 4 No. 3A, 2013, pp. 475-484. doi: 10.4236/jct.2013.43A058.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] B. Coiffier, “Diffuse Large Cell Lymphoma,” Current Opinion in Oncology, Vol. 13, No. 5, 2001, pp. 325-334. doi:10.1097/00001622-200109000-00003
[2] The Non-Hodgkin’s Lymphoma Classification Project, “A Clinical Evaluation of the International Lymphoma Study Group classification of Non-Hodgkin’s lymphoma,” Blood, Vol. 89, No. 11, 1997, pp. 3909-3918.
[3] N. L. Harris, E. S. Jaffe, H. Stein, et al., “A Revised European-American Classification of Lymphoid Neoplasms: A Proposal from the International Lymphoma Study Group,” Blood, Vol. 84, No. 5, 1994, pp. 1361-1392.
[4] The International Non-Hodgkin’s Lymphoma Prognostic Factors Project, “A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma,” New England Journal of Medicine, Vol. 329, No. 14, 1993, pp. 987-994. doi:10.1056/NEJM199309303291402
[5] A. Rosenwald, G. Wright, W. C. Chan, et al., “The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma,” New England Journal of Medicine, Vol. 346, No. 25, 2002, pp. 1937-1947. doi:10.1056/NEJMoa012914
[6] M. A. Shipp, K. N. Ross, P. Tamayo, et al., “Diffuse Large B-Cell Lymphoma Outcome Prediction by Gene-Expression Profiling and Supervised Machine Learning,” Nature Medicine, Vol. 8. No. 1, 2002, pp. 68-74. doi:10.1038/nm0102-68
[7] S. Harada, R. Suzuki, K. Uehira, et al., “Molecular and Immunological Dissection of Diffuse Large B Cell Lymphoma: CD5+, and CD5- with CD10+ Groups May Constitute Clinically Relevant Subtypes,” Leukemia, Vol. 13, No. 9, 1999, pp. 1441-1447. doi:10.1038/sj.leu.2401487
[8] K. Ohshima, C. Kawasaki, H. Muta, et al., “CD10 and Bcl10 Expression in Diffuse Large B-Cell Lymphoma: CD10 is a Marker of Improved Prognosis,” Histopathology, Vol. 39, No. 2, 2001, pp. 156-162. doi:10.1046/j.1365-2559.2001.01196.x
[9] A. A. Alizadeh, M. B. Eisen, R. E. Davis, et al., “Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling,” Nature, Vol. 403, No. 6769, 2000, pp. 503-511. doi:10.1038/35000501
[10] B. E. King, C. Chen, J. Locker, et al., “Immunophenotypic and Genotypic Markers of Follicular Center Cell Neoplasia in Diffuse Large B-Cell Lymphoma,” Modern Pathology, Vol. 13, No. 10, 2000, pp. 1219-1231. doi:10.1038/modpathol.3880226
[11] A. Dogan, E. Bagdi, P. Munson and P. G. Isaacson, “CD10 and BCL-6 Expression in Paraffin Sections of Normal Lymphoid Tissue and B-Cell Lymphomas,” American Journal of Surgical Pathology, Vol. 24, No. 6, 2000, pp. 846-852. doi:10.1097/00000478-200006000-00010
[12] M. Yamaguchi, M. Seto, M. Okamoto, et al., “De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Clinicopathologic Study of 109 Patients,” Blood, Vol. 99, No. 3, 2002, pp. 815-821. doi:10.1182/blood.V99.3.815
[13] H. J. Ree, W. I. Yang, C. W. Kim, et al., “Coexpression of Bcl-6 and CD10 in Diffuse Large B-Cell Lymphomas: Significance of Bcl-6 Expression Patterns in Identifying Germinal Center B-Cell Lymphoma,” Human Pathology, Vol. 32, No. 9, 2001, pp. 954-962. doi:10.1053/hupa.2001.27118
[14] G. Lenz, G. Wright, S. S. Dave, et al., “Stromal Gene Signatures in Large-B-Cell Lymphomas,” New England Journal of Medicine, Vol. 359, No. 22, 2008, pp. 2313-2323. doi:10.1056/NEJMoa0802885
[15] C. P. Hans, D. D. Weisenburger, T. C. Greiner, et al., “Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray,” Blood, Vol. 13, No. 1, 2004, pp. 275-282. doi:10.1182/blood-2003-05-1545
[16] M. Berglund, U. Thunberg, R. M. Amini, et al., “Evaluation of Immunophenotype in Diffuse Large B-Cell Lymphoma and Its Impact on Prognosis,” Modern Pathology, Vol. 18, No. 8, 2005, pp. 1113-1120. doi:10.1038/modpathol.3800396
[17] G. W. van Imhoff, E. J. Boerma, B. van der Holt, et al., “Prognostic Impact of Germinal Center-Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma,” Journal of Clinical Oncology, Vol. 24, No. 25, 2006, pp. 4135-4142. doi:10.1200/JCO.2006.05.5897
[18] H. Nyman, M. Adde, M. L. Karjalainen-Lindsberg, et al., “Prognostic Impact of Immunohistochemically Defined Germinal Center Phenotype in Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy,” Blood, Vol. 109, No. 11, 2007, pp. 4930-4935. doi:10.1182/blood-2006-09-047068
[19] R. Seki, K. Ohshima, T. Fujisaki, et al., “Prognostic Impact of Immunohistochemical Biomarkers in Diffuse Large B-Cell Lymphoma in the Rituximab Era,” Cancer Science, Vol. 100, No. 10, 2009, pp. 1842-1847. doi:10.1111/j.1349-7006.2009.01268.x
[20] K. Fu, D. D. Weisenburger, W. W. Choi, et al., “Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma,” Journal of Clinical Oncology, Vol. 26, No. 28, 2008, pp. 4587-4594. doi:10.1200/JCO.2007.15.9277
[21] D. C. Brown and K. C. Gatter, “Ki67 Protein: The Immaculate Deception?” Histopathology, Vol. 40, No. 1, 2002, pp. 2-11. doi:10.1046/j.1365-2559.2002.01343.x
[22] T. Scholzen and J. Gerdes, “The Ki-67 Protein: From the Known and the Unknown,” Journal of Cellular Physiology, Vol. 182, No. 3, 2000, pp. 311-332. doi:10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
[23] K. Szczuraszek, G. Mazur, M. Jelen, P. Dziegiel, P. Surowiak and M. Zabel, “Prognostic Significance of Ki-67 Antigen Expression in Non-Hodgkin’s Lymphomas,” Anticancer Research, Vol. 28, No. 2A, 2008, pp. 1113-1118.
[24] P. Dziegiel, W. Salwa-Zurawska, J. Zurawski, A. Wojnar and M. Zabel, “Prognostic Significance of Augmented Metallothionein (MT) Expression Correlated with Ki-67 Antigen Expression in Selected Soft Tissue Sarcomas,” Histology and Histopathology, Vol. 20, No. 1, 2005, pp. 83-89. doi:10.1111/j.1600-0609.2012.01778.x
[25] Z. M. Li, J. J. Huang, Y. Xia, et al., “High Ki-67 Expression in Diffuse Large B-Cell Lymphoma Patients with Non-Germinal Center Subtype Indicates Limited Survival Benefit from R-CHOP Therapy,” European Journal of Haematology, Vol. 88, No. 6, 2012, pp. 510-517.
[26] N. Hayabuchi, Y. Shibamoto, K. Nakamura, et al., “Stage I and II Aggressive B-Cell Lymphomas of the Head and Neck: Radiotherapy Alone as a Treatment Option and the Usefulness of the New Prognostic Index B-ALPS,” International Journal of Radiation Oncology Biology Physics, Vol. 55, No. 1, 2003, pp. 44-50. doi:10.1016/S0360-3016(02)03798-7
[27] K. Sunaba, H. Shibuya, N. Okada, T. Amagasa, S. Enomoto and S. Kishimoto “Radiotherapy for Primary Localized (Stage I and II) Non-Hodgkin’s Lymphoma of the Oral Cavity,” International Journal of Radiation Oncology Biology Physics, Vol. 47, No. 1, 2000, pp. 179-183. doi:10.1016/S0360-3016(00)00412-0
[28] M. Oguchi, H. Ikeda, K. Isobe, et al., “Tumor Bulk as a Prognostic Factor for the Management of Localized Aggressive Non-Hodgkin’s Lymphoma: A Survey of the Japan Lymphoma Radiation Therapy Group,” International Journal of Radiation Oncology Biology Physics, Vol. 48, No. 1, 2000, pp. 161-168. doi:10.1016/S0360-3016(00)00480-6
[29] M. Yamaguchi, N. Nakamura, R. Suzuki, et al., “De novo CD5+ Diffuse Large B-Cell Lymphoma: Results of a Detailed Clinicopathological Review in 120 Patients,” Hematologica, Vol. 93, No. 8, 2008, pp. 1195-1202. doi:10.3324/haematol.12810
[30] S. Monti, K. J. Savage, J. L. Kutok, et al., “Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response,” Blood, Vol. 105, No. 5, 2005, pp. 1851-1861. doi:10.1182/blood-2004-07-2947
[31] C. Adida, C. Haioun, P. Gaulard, et al., “Prognostic Significance of Surviving Expression in Diffuse Large B-Cell Lymphomas,” Blood, Vol. 96, No. 5, 2000, pp. 1921-1925.
[32] A. Zhang, K. Ohshima, K. Sato, et al., “Prognostic Clinicopathologic Factors, Including Immunologic Expression in Diffuse Large B-Cell Lymphomas,” Pathology International, Vol. 49, No. 12, 1999, pp. 1043-1052. doi:10.1046/j.1440-1827.1999.00980.x
[33] M. Takeshita, A. Iwashita, K. Kurihara, et al., “Histologic and Immunohistologic Findings and Prognosis of 40 Cases of Gastric Large B-Cell Lymphoma,” The American Journal of Surgical Pathology, Vol. 24, No. 12, 2000, pp. 1641-1649. doi:10.1097/00000478-200012000-00008
[34] L. Colomo, A. López-Guillermo, M. Perales, et al., “Clinical Impact of the Differentiation Profile Assessed by Immunophenotyping in Patients with Diffuse Large B-Cell Lymphoma,” Blood, Vol. 101, No. 1, 2003, pp. 78-84. doi:10.1182/blood-2002-04-1286
[35] C. C. Chang, S. McClintock, R. P. Cleveland, et al., “Immunohistochemical Expression Patterns of Germinal Center and Activation B-Cell Markers Correlate with Prognosis in Diffuse Large B-Cell Lymphoma,” The American Journal of Surgical Pathology, Vol. 28, No. 4, 2004, pp. 464-470. doi:10.1097/00000478-200404000-00005
[36] T. Katzenberger, A. Lohr, S. Schwarz, et al., “Genetic Analysis of de Novo CD5+ Diffuse Large B-Cell Lymphomas Suggests an Origin from a Somatically Mutated CD5+ Progenitor B Cell,” Blood, Vol. 101, No. 2, 2003, pp. 699-702. doi:10.1182/blood-2002-06-1726
[37] P. Feugier, A. Van Hoof, C. Sebban, et al., “Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Study by the Groupe d’Etude des Lymphomes de l’Adulte,” Journal of Clinical Oncology, Vol. 23, No. 18, 2005, pp. 4117-4126. doi:10.1200/JCO.2005.09.131
[38] J. N. Winter, E. A. Weller, S. J. Horning, et al., “Prognostic Significance of Bcl-6 Protein Expression in DLBCL Treated with CHOP or R-CHOP: A Prospective Correlative Study,” Blood, Vol. 107, No. 11, 2006, pp. 4207-4213. doi:10.1182/blood-2005-10-4222
[39] N. Mounier, J. Briere, C. Gisselbrecht, et al., “Rituximab Plus CHOP (R-CHOP) Overcomes bcl-2-Associated Resistance to Chemotherapy in Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL),” Blood, Vol. 101, No. 11, 2003, pp. 4279-4284. doi:10.1182/blood-2002-11-3442

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.